For immediate release | 3 May 2023 |
Gooch & Housego PLC
("G&H" or the "Company")
Issue of Equity
Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components & systems, announces that it has applied for the admission to trading on AIM of 11,275 new ordinary shares of 20p each in the Company ("Ordinary Shares") following the exercise of certain options over Ordinary Shares. Dealings are expected to commence on 9 May 2023.
Following the issue of the 11,275 new Ordinary Shares, the total number of Ordinary shares in issue as at the date of this notice is 25,052,194 with each share carrying the right to one vote. There are no shares held in Treasury. The total number of voting rights in the Company is, therefore, 25,052,194.
The above figure of 25,052,194 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.
For further information please contact:
Charlie Peppiatt, Chief Executive Officer Chris Jewell, Chief Financial Officer | Gooch & Housego PLC | +44 (0) 1460 256440 |
|
| |
Mark Court / George Cleary | Buchanan | +44 (0) 20 7466 5000 |
|
| |
Christopher Baird / David Anderson | Investec Bank plc (Nomad & broker) | +44 (0) 20 7597 5970 |
Notes to editors
1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.